These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 3283626

  • 21. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.
    J Clin Oncol; 2014 Jan 20; 32(3):219-28. PubMed ID: 24297940
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A, Mizoguchi H, Hoshino S, Nomura T, Dan K, Toyama K, Kimura M, Ogawa T, Yamaguchi H, Mutoh Y.
    Int J Hematol; 1991 Feb 20; 54(1):75-7. PubMed ID: 1954354
    [Abstract] [Full Text] [Related]

  • 25. [Treatment of various types of acute leukemia in adult. An analysis of 98 cases. The Leukemia Cooperation Group of Beijing City].
    Zhonghua Nei Ke Za Zhi; 1992 Mar 20; 31(3):139-42, 187. PubMed ID: 1395923
    [Abstract] [Full Text] [Related]

  • 26. Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
    Ohno R, Yokomaku S, Okumara M, Tanimoto M, Morishita Y, Morishima Y, Kodera Y, Saito H.
    Haematol Blood Transfus; 1990 Mar 20; 33():304-8. PubMed ID: 2182424
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L.
    Blood; 1984 May 20; 63(5):1039-45. PubMed ID: 6201211
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    Peters WG, Willemze R, Colly LP.
    Eur J Haematol; 1988 Mar 20; 40(3):198-204. PubMed ID: 3162718
    [Abstract] [Full Text] [Related]

  • 35. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.
    Ann Hematol; 2014 Dec 20; 93(12):2011-8. PubMed ID: 24989345
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
    Lou FD, Zhou Q, Meng FY.
    Zhonghua Nei Ke Za Zhi; 1992 Mar 20; 31(3):146-8, 187. PubMed ID: 1395925
    [Abstract] [Full Text] [Related]

  • 38. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
    Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T.
    Gan To Kagaku Ryoho; 2007 Nov 20; 34(11):1793-8. PubMed ID: 18030012
    [Abstract] [Full Text] [Related]

  • 39. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P.
    Am J Hematol; 2014 Apr 20; 89(4):399-403. PubMed ID: 24375467
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.